<DOC>
	<DOCNO>NCT02071823</DOCNO>
	<brief_summary>The objective study characterize effect food pharmacokinetics ( PK ) tolerability BIA 9-1067 healthy male subject .</brief_summary>
	<brief_title>Comparative Bioavailability Study BIA 9-1067 25 mg Capsules</brief_title>
	<detailed_description>Methodology : Single center , randomize , single dose , open-label , 2-period , 2-sequence , crossover study .</detailed_description>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Availability entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer Male volunteer Volunteer age least 18 year old 45 year Volunteer body mass index ( BMI ) great equal 18.5 30 kg/m2 Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance Healthy accord medical history , laboratory result physical examination Light , non exsmokers . A light smoker define someone smoking 10 cigarette less per day least 3 month day 1 study . An exsmoker define someone completely stop smoke least 12 month day 1 study The informed consent form must sign volunteer , prior participation study . Volunteers present follow include study : Significant history hypersensitivity catecholstructured drug ( e.g . rimiterole , isoprenaline , adrenaline , noradrenaline , dopamine , dopexamine dobutamide ) relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect History significant gastrointestinal , liver kidney disease may affect drug bioavailability Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic , dermatologic connective tissue disease Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease Presence significant heart disease disorder accord ECG Previous history Neuroleptic Malignant Syndrome ( NMS ) and/or nontraumatic rhabdomyolysis Pheochromocytoma due increase risk hypertensive crisis Use MAO inhibitor within 14 day day 1 study Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day day 1 study Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse Any history tuberculosis and/or prophylaxis tuberculosis Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Opicapone ,</keyword>
	<keyword>Parkinson ,</keyword>
	<keyword>Bial ,</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>